Breast Cancer Burden and Disparities Among Underserved Women: Lessons from a Community-based Partici

来源 :2016第九届世界癌症大会 | 被引量 : 0次 | 上传用户:zemao1988
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Breast cancer is the most common cancer in women worldwide and second leading cause of deaths among women in the United States.
其他文献
Oral squamous cell carcinoma (OSCC),the sixth most common human malignancy has the highest morbidity and mortality,and a survival rate of approximately 50% at 5 years from diagnosis.
会议
Radiotherapy is a common treatment for esophagel cancer.However,radioresistance remains a fundamental barrier for obtaining the maximal efficacy.
会议
Social support has been shown to provide many benefits to the overall health and well-being of breast cancer patients.However,breast cancer patients,especially in Asia,frequently do not receive adequa
会议
In the United States of America,there are approximately 2.9 million breast cancer survivors;many have undergone a mastectomy with or without radiation.
会议
The intrinsic or acquired drug resistance is the main challenge for cancer chemotherapy today.So far,many nanosized drug delivery systems (NDDS) have been exploited to combat cancer drug resistance.
会议
Paraffin-embedded tumor tissues from 141 breast cancer patients were selected in 2000-2014 and classified into luminal A,luminal B,HER2+ and triple-negative subtypes.
会议
Introduction: Central quadrantectomy with nipple-areola complex (NAC) resection removes a cylinder of breast tissue deep down to the pectoral muscle.
会议
Paragangliomas are relatively rare chromaffin cell tumors which may be cured through resection.Patients with paragangliomas may develop metastatic diseases.
会议
Breast cancer is one of the major killers among malignant conditions worldwide,affecting one,out of 10 women in industrialized countries,and being the leading cause of cancer-related morbidity and mor
会议
Extended adjuvant endocrine therapy (10 vs.5 years) trials have demonstrated improved outcomes in early-stage estrogen receptor (ER)-positive breast cancer;however,the absolute benefit is modest,and t
会议